Metabolic and hemodynamic effects of combined treatment with metformine and rosiglitasone (avandium) in patients with diabetes mellitus type 2 and high cardiovascular risk
Abstract
AIM: To study efficiacy of 24-week combined therapy with metformin and rosiglitasone in correction of metabolic parameters, blood pressure and total cardiovascular risk in patients with diabetes mellitus type 2.
MATERIAL AND METHODS: Blood pressure, body mass, glycemia and blood lipids, hyperinsulinemia, fat mass were studied in 30 patients with diabetes mellitus type 2 and hypertension on metformine treatment in a dose 1500 mg/day. When they entered the trial, metformine treatment was combined with rosiglitasone in a dose 4 mg/day. The combined treatment continued for 24 weeks.
RESULTS: The above combination significantly improved carbohydrate and lipid metabolism. The levels of fasting and postprandial glycemia, glycosylated hemoglobin, insulin resistance index significantly reduced. Both total and visceral fat tissue mass diminished. Improvement was seen in 24-h blood pressure monitoring data and intracardiac hemodynamics. Total cardiovascular risk decreased by three scales. Side effects were not registered.
CONCLUSION: Combined use of metformine and rosiglitasone in patients with diabetes type 2 is pathogenetically sound, highly effective and safe.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 30 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.